Therapeutic Category
Anticoagulant
ELIBAN
Targeted Anticoagulant Therapy
Anticoagulant Brand
ELIBAN
ELIBAN contains apixaban, a direct and selective Factor Xa inhibitor used for the prevention and treatment of thromboembolic disorders.
Dosage form
Tablets
Strength Available
2.5mg, 5mg
Pack sizes
Pack of 3x10, 3x20 Tablets
Therapeutic Indications
- ELIBAN is indicated in adults for the prevention and treatment of thromboembolic events, including DVT, PE, and stroke/systemic embolism associated with non-valvular atrial fibrillation.
Packshot not available
Brand Name
ELIBAN
Product Name
ELIBAN 2.5 Tablets
Generic Name
Apixaban 2.5mg Tablets
Dosage Form
Tablets
Pack Size
Pack of 3x10 Tablets
Therapeutic Indication
Prevention and treatment of blood clots after hip or knee replacement surgery, prevention of recurrent DVT/PE after at least 6 months of treatment, and prevention of stroke/systemic embolism in selected patients with non-valvular atrial fibrillation.
Dosage and Method of Administration
- Hip/knee replacement: 2.5 mg twice daily; first dose 12–24 hours after surgery.
- Recurrent DVT/PE prevention: 2.5 mg twice daily after at least 6 months of initial treatment.
- Non-valvular AF: 2.5 mg twice daily when dose reduction criteria are met.
Mode of Administration
For oral use only.
Packshot not available
Brand Name
ELIBAN
Product Name
ELIBAN 5 Tablets
Generic Name
Apixaban 5mg Tablets
Dosage Form
Tablets
Pack Size
Pack of 3x20 Tablets
Therapeutic Indication
Prevention and treatment of stroke and systemic embolism in adults with non-valvular atrial fibrillation, and treatment of DVT and PE.
Dosage and Method of Administration
- Non-valvular AF: 5 mg twice daily.
- DVT/PE treatment: 10 mg twice daily for the first 7 days, followed by 5 mg twice daily.
Mode of Administration
For oral use only.